Who founded Intact Therapeutics?

Intact Therapeutics was founded by Ravi Pamnani, Sidhartha Sinha in 2015.

Who are Intact Therapeutics's investors?

Intact Therapeutics's investors include Brightstone Venture Capital, Y Combinator.

Where is Intact Therapeutics headquartered?

Intact Therapeutics is headquartered in San Francisco, US.

Intact Therapeutics

YC W19

San Francisco, US · Founded 2015 · 4 employees · 2 known investors

Find your way into Intact Therapeutics

1,606 people in our graph share verified history with the Intact Therapeutics team — schools, employers, funds. One of them is your warm intro.

Paul Kwanunlockedknows Ravi Pamnani · together at Stanford University (overlapped)

×6knows the team · via Stanford University

×4knows the team · via Y Combinator

knows the team · via Guidant Corporation

Intact Therapeutics develops next-generation biopharmaceutical therapies for gastrointestinal diseases to address unmet clinical needs. The company is clinical-stage and focused on improving patient outcomes through innovative medicines.

Biotech Healthtech Drug Delivery TherapeuticsUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (W19)

Intact Therapeutics was founded in 2015 by Ravi Pamnani and Sidhartha Sinha.

Ravi Pamnani inCEO & Co-FounderFounder and CEO of Intact Therapeutics, a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases.

Sidhartha SinhainFounder

Investors · 2

Brightstone Venture CapitalMinneapolis · $250K – $10M

Y CombinatorSan Francisco · $500K

Competitors · 4

by search overlap

Intracellular Therapies5 shared keywordsA biopharmaceutical company developing treatments for psychiatric and neurologic disorders based on research into how therapies affect cellular mechanisms. The company, now part of Johnson & Johnson, focuses on innovative therapies for patients with complex brain-related diseases.

Iteriontherapeutics3 shared keywordsIterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.

Entactbio3 shared keywordsEntact is a drug discovery company developing treatments for patients. It works in the biotechnology and therapeutics sector.

Incyte Corporation3 shared keywordsIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.

Companies competing with Intact Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$296.5K
National Science Foundation	Phase I	2020	$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Intact Therapeutics do?: Intact Therapeutics develops next-generation biopharmaceutical therapies for gastrointestinal diseases to address unmet clinical needs. The company is clinical-stage and focused on improving patient outcomes through innovative medicines.
Who founded Intact Therapeutics?: Intact Therapeutics was founded by Ravi Pamnani, Sidhartha Sinha in 2015.
Who are Intact Therapeutics's investors?: Intact Therapeutics's investors include Brightstone Venture Capital, Y Combinator.
Where is Intact Therapeutics headquartered?: Intact Therapeutics is headquartered in San Francisco, US.